The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Stephan Spahn,Fabian Kleinhenz,Ekaterina Shevchenko,Aaron Stahl,Yvonne Rasen,Christine Geisler,Kristina Ruhm,Marion Klaumuenzer,Thales Kronenberger,Stefan A. Laufer,Holly Sundberg-Malek,Khac Cuong Bui,Marius Horger,Saskia Biskup,Klaus Schulze-Osthoff,Markus Templin,Nisar P. Malek,Antti Poso,Michael Bitzer

DOI: https://doi.org/10.1038/s41467-024-45247-6

IF: 16.6

2024-02-12

Nature Communications

Abstract:Abstract Fibroblast growth factor receptor (FGFR)−2 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a characteristic pattern of adverse events or evocation of kinase domain mutations. A comprehensive characterization of a patient cohort treated with the non-selective TKI lenvatinib reveals promising efficacy in FGFR2-driven CCA. In a bed-to-bench approach, we investigate FGFR2 fusion proteins bearing critical tumor-relevant point mutations. These mutations confer growth advantage of tumor cells and increased resistance to selective TKIs but remain intriguingly sensitive to lenvatinib. In line with clinical observations, in-silico analyses reveal a more favorable interaction pattern of lenvatinib with FGFR2, including an increased flexibility and ligand efficacy, compared to FGFR-selective TKIs. Finally, the treatment of a patient with progressive disease and a newly developed kinase mutation during therapy with a selective inhibitor results in a striking response to lenvatinib. Our in vitro, in silico, and clinical data suggest that lenvatinib is a promising treatment option for FGFR2-driven CCA, especially when insurmountable adverse reactions of selective TKIs or acquired kinase mutations occur.

multidisciplinary sciences